Literature DB >> 1335459

Glucose metabolism and hypoglycaemia in SIDS.

A Burchell1, H Lyall, A Busuttil, E Bell, R Hume.   

Abstract

Once a child is born its survival depends on the maturation of the blood glucose homeostatic control mechanisms. When this fails or where there is an inborn error of metabolism the infant is susceptible to potentially fatal hypoglycaemic episodes. A variety of environmental stresses, either singly or in combination, such as inappropriate or low caloric intake, acute infections of childhood, endotoxaemia, fever, xenobiotic exposure, oxidative stress or anaphylaxis, can greatly exacerbate the deficiency of the normal homeostatic compensatory mechanism and result in the onset of hypoglycaemia. Various inborn errors have been found in infants who died of SIDS. Our approach to this problem has been to use the six microsomal glucose-6-phosphatase proteins as a model system to study defects in carbohydrate metabolism in cases of SIDS. Initial studies determined the ontogeny of the glucose-6-phosphatase proteins and showed that intact microsomes isolated from unfrozen liver samples can be used to study glucose-6-phosphatase in cases of SIDS that were presumably due to the low concentrations of liver lipid peroxidation. More recently we have used a combination of techniques to demonstrate the abnormalities of glucose-6-phosphatase in cases of SIDS. Classic gross pathology and histology have now clearly defined the various subgroups of sudden and unexpected deaths of infancy. This now enables us to develop new molecular approaches to predict and prevent hypoglycaemia in infants who are at risk of SIDS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335459

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Therapeutic insulin and hepatic glucose-6-phosphatase activity in preterm infants.

Authors:  A Burchell; A McGeechan; R Hume
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

2.  Characterization of the human liver fructose-1,6-bisphosphatase gene promoter.

Authors:  B Herzog; M Waltner-Law; D K Scott; K Eschrich; D K Granner
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

3.  An inadequate glycaemic response to glucagon is linked to insulin resistance in preterm infants?

Authors:  L Jackson; A Burchell; A McGeechan; R Hume
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

Review 4.  Biochemical screening in newborn siblings of cases of SIDS.

Authors:  A Green
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

5.  Immunohistochemical localisation of glucose-6-phosphatase in developing human kidney.

Authors:  R Hume; J E Bell; A Hallas; A Burchell
Journal:  Histochemistry       Date:  1994-07

6.  Identification of novel polymorphisms in the glucokinase and glucose-6-phosphatase genes in infants who died suddenly and unexpectedly.

Authors:  Laura Forsyth; Robert Hume; Allan Howatson; Anthony Busuttil; Ann Burchell
Journal:  J Mol Med (Berl)       Date:  2005-05-26       Impact factor: 4.599

7.  The human embryonic-fetal kidney endoplasmic reticulum phosphate-pyrophosphate transport protein.

Authors:  R Hume; H Brewerton; A Burchell
Journal:  Virchows Arch       Date:  1996-03       Impact factor: 4.064

8.  Is shock a key element in the pathology of sudden infant death syndrome (SIDS)?

Authors:  Jane Blood-Siegfried; Margaret T Bowers; Marcia Lorimer
Journal:  Biol Res Nurs       Date:  2008-12-28       Impact factor: 2.522

9.  The glucose-6-phosphatase enzyme in developing human trachea and oesophagus.

Authors:  R Hume; A Burchell
Journal:  Histochem J       Date:  1996-02

10.  Genetic and Environmental Factors Affecting TNF-α Responses in Relation to Sudden Infant Death Syndrome.

Authors:  Sophia M Moscovis; Ann E Gordon; Osama M Al Madani; Maree Gleeson; Rodney J Scott; Sharron T Hall; Christine Burns; Caroline Blackwell
Journal:  Front Immunol       Date:  2015-07-27       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.